219 related articles for article (PubMed ID: 34328195)
1. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
2. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
3. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Uzawa K; Amelio AL; Kasamatsu A; Saito T; Kita A; Fukamachi M; Sawai Y; Toeda Y; Eizuka K; Hayashi F; Kato-Kase I; Sunohara M; Iyoda M; Koike K; Nakashima D; Ogawara K; Endo-Sakamoto Y; Shiiba M; Takiguchi Y; Yamauchi M; Tanzawa H
Sci Rep; 2019 Aug; 9(1):12179. PubMed ID: 31434965
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas.
Yin J; Jung JE; Choi SI; Kim SS; Oh YT; Kim TH; Choi E; Lee SJ; Kim H; Kim EO; Lee YS; Chang HJ; Park JY; Kim Y; Yun T; Heo K; Kim YJ; Kim H; Kim YH; Park JB; Choi SW
Cancer Lett; 2018 Feb; 414():181-189. PubMed ID: 29154973
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.
Tsuchihashi H; Naruse T; Yanamoto S; Okuyama K; Furukawa K; Omori K; Umeda M
Oncol Rep; 2020 Sep; 44(3):863-872. PubMed ID: 32705230
[TBL] [Abstract][Full Text] [Related]
7. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
8. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
[TBL] [Abstract][Full Text] [Related]
9. Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway.
Su W; Wang Y; Wang F; Sun S; Li M; Shen Y; Yang H
BMC Cancer; 2019 Apr; 19(1):400. PubMed ID: 31035951
[TBL] [Abstract][Full Text] [Related]
10. Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.
Yasui H; Ohnishi Y; Nakajima M; Nozaki M
Oncol Rep; 2017 Jun; 37(6):3674-3680. PubMed ID: 28440510
[TBL] [Abstract][Full Text] [Related]
11. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
13. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
Harada K; Ferdous T; Kobayashi H; Ueyama Y
Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
[TBL] [Abstract][Full Text] [Related]
16. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/Akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation.
Hu S; Li S; Xu Y; Huang X; Mai Z; Chen Y; Xiao H; Ning W; Gaus S; Savkovic V; Lethaus B; Zimmerer R; Acharya A; Ziebolz D; Schmalz G; Huang S; Zhao J; Hu X
Phytomedicine; 2024 Jun; 128():155488. PubMed ID: 38493718
[TBL] [Abstract][Full Text] [Related]
20. Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma.
Wang H; Deng X; Zhang J; Ou Z; Mai J; Ding S; Huo S
Cell Physiol Biochem; 2017; 44(3):920-934. PubMed ID: 29176314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]